Androgen receptor antagonists for prostate cancer therapy
about
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerThe endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancerHigh progesterone receptor expression in prostate cancer is associated with clinical failure.BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patientsAndrogen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle Atrophy.Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target.Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.Structure-activity relationship analysis of carbobicyclo and oxabicyclo succinimide analogs as potential androgen receptor antagonists.Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.Prostate cancer cell proliferation is suppressed by microRNA-3160-5p via targeting of F-box and WD repeat domain containing 8.Endocrine Disruption at the Androgen Receptor: Employing Molecular Dynamics and Docking for Improved Virtual Screening and Toxicity Prediction.Inflammation and NF-κB Signaling in Prostate Cancer: Mechanisms and Clinical Implications
P2860
Q26750620-2133AF09-D730-4AB7-B379-2C3683607056Q27348356-3F5EB16E-2784-405E-989E-E33A7FC056A8Q34462138-0DBEA5C2-DE57-493E-93C0-1CC356384762Q35130208-1AECB043-302E-437B-A825-AD3AE456A1D0Q36905832-2947AF6C-EA31-4CDB-9255-1D1B0EF0DBB2Q37682137-3E071509-382C-4F0F-ACF8-43E3E6CFC296Q38632050-0155817C-E390-4109-8986-5D2DC9BB2373Q38661520-878B20FB-9249-43AC-B57B-6F69BDB17641Q39309007-7D906F16-9EB0-414F-8622-6634F3138D9EQ41832140-A62DFB4F-611B-4CEC-AEF4-F049BD263AAFQ53098808-9469E17C-E001-40CF-BBE7-1F535331A9CBQ53686355-593BCA5F-9736-4A5D-91CA-EB2D926259ABQ55037660-B18ACCB8-8409-4B7B-95BE-42C97DF98CBCQ55669060-61B2D702-2051-4951-8F80-3D271F19E6BEQ57107409-52C22868-EA98-48FA-8BB8-7AF814A10E7D
P2860
Androgen receptor antagonists for prostate cancer therapy
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Androgen receptor antagonists for prostate cancer therapy
@ast
Androgen receptor antagonists for prostate cancer therapy
@en
Androgen receptor antagonists for prostate cancer therapy
@nl
type
label
Androgen receptor antagonists for prostate cancer therapy
@ast
Androgen receptor antagonists for prostate cancer therapy
@en
Androgen receptor antagonists for prostate cancer therapy
@nl
prefLabel
Androgen receptor antagonists for prostate cancer therapy
@ast
Androgen receptor antagonists for prostate cancer therapy
@en
Androgen receptor antagonists for prostate cancer therapy
@nl
P2093
P356
P1476
Androgen receptor antagonists for prostate cancer therapy
@en
P2093
Arnout Voet
Christine Helsen
Frank Claessens
Hendrik Van Poppel
Stefan Prekovic
Steven Joniau
Thomas Van den Broeck
P304
P356
10.1530/ERC-13-0545
P407
P577
2014-08-01T00:00:00Z